Navigation Links
Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
Date:10/8/2008

PRINCETON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems Conference being held from October 13-14, 2008 at the Waldorf Astoria in New York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide an overview of the company on Monday, October 13, 2008, at 11:30 AM (ET).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E.T. Smith

Vice President of Investor Relations

richard.smith@pharmasset.com

Office: +1 (609) 613-4181


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
2. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
3. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
4. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
5. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
6. Pharmasset Joins Russell 3000 Index
7. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
8. Pharmasset Selected to Join the NASDAQ Biotechnology Index
9. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
10. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
11. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... their findings on what they believe could be a new and helpful biomarker ... new research. Click here to read it now. , Biomarkers are ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):